Jiangsu Nanfang Medical Co., Ltd. (SHA:603880)
China · Delayed Price · Currency is CNY 6.68
+0.03 (0.45%)
Feb 13, 2026, 3:00 PM CST
Jiangsu Nanfang Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 594.26 | 602.01 | 599.66 | 544.78 | 523.74 | 1,071 |
Other Revenue | 0.6 | 0.6 | 0.43 | 0.59 | 3.7 | 1.04 |
| 594.86 | 602.62 | 600.1 | 545.37 | 527.44 | 1,072 | |
Revenue Growth (YoY) | 1.71% | 0.42% | 10.04% | 3.40% | -50.82% | 118.11% |
Cost of Revenue | 632.48 | 631.53 | 566.33 | 477.73 | 432.92 | 722.59 |
Gross Profit | -37.62 | -28.91 | 33.76 | 67.63 | 94.52 | 349.81 |
Selling, General & Admin | 91.82 | 94.79 | 59.95 | 56.17 | 70.97 | 159.97 |
Research & Development | 27.23 | 28.72 | 28.18 | 27.73 | 30.62 | 33.96 |
Other Operating Expenses | 6.14 | 4.22 | 6.52 | 5.66 | 4.35 | 10.16 |
Operating Expenses | 111.55 | 111.2 | 124.54 | 93.99 | 110.53 | 213.33 |
Operating Income | -149.17 | -140.11 | -90.77 | -26.36 | -16.01 | 136.48 |
Interest Expense | -36.83 | -26.43 | -23.19 | -20.18 | -11.8 | -7.6 |
Interest & Investment Income | 8.38 | 8.69 | 9.15 | 9.38 | 8.8 | 12.2 |
Earnings From Equity Investments | 0.54 | - | - | - | - | - |
Currency Exchange Gain (Loss) | -1.04 | -1.04 | 0.58 | 5.85 | -3.76 | -14.33 |
Other Non Operating Income (Expenses) | 2.45 | -0.7 | -9.33 | -1.53 | -6.67 | -10.39 |
EBT Excluding Unusual Items | -175.67 | -159.59 | -113.56 | -32.85 | -29.43 | 116.36 |
Gain (Loss) on Sale of Investments | - | - | 1.3 | 1.23 | - | - |
Gain (Loss) on Sale of Assets | -0.14 | -0.21 | -4.29 | -0.03 | 0.05 | 0.02 |
Asset Writedown | -40.24 | -38.4 | -34.17 | - | -2.48 | -16.09 |
Other Unusual Items | 1.47 | -2.66 | 2.2 | 2.31 | 1.17 | 9.59 |
Pretax Income | -214.57 | -200.86 | -148.52 | -29.34 | -30.69 | 109.89 |
Income Tax Expense | -12.12 | -10.36 | -1.23 | -14.41 | -7.65 | 11.6 |
Earnings From Continuing Operations | -202.45 | -190.5 | -147.29 | -14.94 | -23.04 | 98.28 |
Minority Interest in Earnings | 0.17 | -0.17 | -0.13 | 0.29 | 0.28 | -0.22 |
Net Income | -202.28 | -190.67 | -147.42 | -14.65 | -22.76 | 98.07 |
Net Income to Common | -202.28 | -190.67 | -147.42 | -14.65 | -22.76 | 98.07 |
Net Income Growth | - | - | - | - | - | 249.60% |
Shares Outstanding (Basic) | 289 | 289 | 289 | 293 | 285 | 286 |
Shares Outstanding (Diluted) | 289 | 293 | 289 | 293 | 285 | 286 |
Shares Change (YoY) | 0.34% | 1.48% | -1.34% | 2.97% | -0.60% | 2.66% |
EPS (Basic) | -0.70 | -0.66 | -0.51 | -0.05 | -0.08 | 0.34 |
EPS (Diluted) | -0.70 | -0.66 | -0.51 | -0.05 | -0.08 | 0.34 |
EPS Growth | - | - | - | - | - | 240.56% |
Free Cash Flow | 74.09 | 30.92 | -50.65 | -114.88 | -296.01 | 30.83 |
Free Cash Flow Per Share | 0.26 | 0.10 | -0.17 | -0.39 | -1.04 | 0.11 |
Dividend Per Share | - | - | - | - | - | 0.115 |
Dividend Growth | - | - | - | - | - | 289.87% |
Gross Margin | -6.32% | -4.80% | 5.63% | 12.40% | 17.92% | 32.62% |
Operating Margin | -25.08% | -23.25% | -15.13% | -4.83% | -3.03% | 12.73% |
Profit Margin | -34.01% | -31.64% | -24.57% | -2.69% | -4.32% | 9.14% |
Free Cash Flow Margin | 12.46% | 5.13% | -8.44% | -21.07% | -56.12% | 2.88% |
EBITDA | -102.3 | -90.07 | -36.5 | 14.86 | 12.87 | 156.78 |
EBITDA Margin | -17.20% | -14.95% | -6.08% | 2.73% | 2.44% | 14.62% |
D&A For EBITDA | 46.87 | 50.04 | 54.27 | 41.22 | 28.88 | 20.31 |
EBIT | -149.17 | -140.11 | -90.77 | -26.36 | -16.01 | 136.48 |
EBIT Margin | -25.08% | -23.25% | -15.13% | -4.83% | -3.03% | 12.73% |
Effective Tax Rate | - | - | - | - | - | 10.56% |
Revenue as Reported | 594.86 | 602.62 | 600.1 | 545.37 | 527.44 | 1,072 |
Advertising Expenses | - | 1.97 | 1.09 | 0.67 | 0.48 | 0.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.